Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 12/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | KIT | P10721 | 4/20 | 0.49 |
| ▸ | BRAF | P15056 | 3/20 | 0.49 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869371 | 0.93 | JAK2 (0.66) | NPC1RAB9AJAK2JAK1KDR | |
| SCHEMBL4034467 | 0.88 | NPC1 (0.55) | NPC1RAB9AHPGDSMN1; SMN2JAK2 | |
| SCHEMBL6543870 | 0.87 | KIT (0.63) | NPC1RAB9AHPGDSMN1; SMN2JAK2 | |
| SCHEMBL4034472 | 0.85 | NPC1 (0.52) | NPC1RAB9AHPGDSMN1; SMN2JAK2 | |
| SCHEMBL4042755 | 0.85 | NPC1 (0.52) | NPC1RAB9AHPGDSMN1; SMN2JAK2 | |
| SCHEMBL3870092 | 0.81 | FLT1 (0.48) | KDRFLT1KITBRAFCSF1R | |
| SCHEMBL3868951 | 0.81 | JAK2 (0.66) | NPC1RAB9AJAK2JAK1KDR | |
| SCHEMBL6543933 | 0.80 | JAK2 (0.64) | NPC1RAB9AJAK2JAK1KDR | |
| SCHEMBL6786372 | 0.80 | KDR (0.57) | NPC1RAB9AHPGDSMN1; SMN2JAK2 | |
| SCHEMBL3864318 | 0.79 | NOTUM (0.49) | KDRFLT1KITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615565-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517894-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7148357-B2 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | SCHERING AG (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1594841-A1 | VEGFR-2 AND VEGFR-3 INHIBITORY ANTHRANYLAMIDOPYRIDINES | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-16 | — | — | EP | disclosed |
| CN-1671666-A | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridine compounds | SCHERING AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| CN-1518546-A | Selective anthranilamide picolinamides as VEGRF-2 and VEGFR-3 inhibitors | ���ֹɷݹ�˾ | 2004-08-04 | — | — | CN | disclosed |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004013102-A1 | VEGFR-2 AND VEGFR-3 INHIBITORY ANTHRANYLAMIDOPYRIDINES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015794-A1 | Endothelial growth factor; angiogenesis inhibitors; antitumor agents; skin disorders; endimetriosis; Crohn's disease; leukemia; antiarthritic agents | FLT4, KDR, FLT1 | NPC1 4870/4885RAB9A 2587/4885HPGD 2911/4885 |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | NPC1 4864/4885RAB9A 1818/4885HPGD 2323/4885 |
| US-20040147535-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | NPC1 4839/4885RAB9A 1702/4885HPGD 2498/4885 |
| US-20050054654-A1 | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines | FLT4, KDR, FLT1 | NPC1 4841/4885RAB9A 1703/4885HPGD 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.